Previous 10 | Next 10 |
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open , an ATP 250 tournament, and a partnership with San...
DermTech, Inc. has developed an innovative, non-invasive test to diagnose skin cancer and other conditions. DMTK’s SmartSticker solution is not only proprietary but has been shown to be more effective and accurate than traditional biopsy-based diagnostic approaches. Analyst...
DermTech (NASDAQ: DMTK) is trying to redefine the process for identifying skin cancer. The current approach involves a visual inspection and an invasive biopsy -- a highly inaccurate method that most patients don't like. DermTech's products help consumer avoid worrying about accurac...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN: The Journal Of Cutaneous Medicine has published research including the results of DermTech’s TRUST stu...
DermTech (NASDAQ: DMTK) stock skyrocketed earlier this year. Now, though, its shares are more than 50% below the previous highs. In this Motley Fool Live video recorded on Sept. 1 , Motley Fool contributors Keith Speights and Brian Orelli address a viewer's question abo...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it is presenting at the 2021 Florida Association of Health Plans (“FAHP”) annual conference on November 14-16,...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will participate at the Lake Street 2021 BIG5 Conference on Tuesday, September 14, 2021. About DermTech...
DermTech is harnessing the power of Precision Dermatology to eradicate death from skin cancer. Precision Dermatology works extremely well in detecting early stage of the deadly skin cancer, melanoma. Revenues are ramping up as the company is expanding its sales and marketing force...
Shares of DermTech (NASDAQ: DMTK) lost 19% of their value in July, according to data provided by S&P Global Intelligence . The stock opened at $41.24 when the market opened on July 1 but was down to $33.66 at the close on July 30. The stock's nadir in the month came on July ...